Standard BioTools (LAB) 8-K: Equity Plan Expanded, Directors Elected

Rhea-AI Filing Summary

Standard BioTools Inc. (Nasdaq: LAB) filed an 8-K reporting the outcomes of its 2025 Annual Meeting held on 18 June 2025. Shareholder turnout was high, with 326,864,517 votes cast, representing approximately 86.06% of the 379,822,268 shares outstanding on the 25 April 2025 record date.

The meeting covered four key proposals, all of which passed with comfortable majorities:

• Election of two Class III directors: Kathy Hibbs (96.2% support) and Frank Witney, Ph.D. (97.9% support) were elected to serve until the 2028 annual meeting.
• Say-on-Pay: Executive compensation for FY 2024 received 97.0% shareholder approval (241.1 million FOR vs. 4.0 million AGAINST).
• Auditor ratification: PricewaterhouseCoopers LLP was re-appointed for FY 2025 with 98.8% support (322.9 million FOR).
• Equity Incentive Plan amendment: Shareholders approved increasing the Amended and Restated 2011 Equity Incentive Plan share reserve by 17.4 million shares (223.4 million FOR, 19.6 million AGAINST).

The additional share reserve expands the pool available for future equity grants to employees and directors. Full plan details are provided in Exhibit 10.1, with prior discussion in the company’s 30 April 2025 proxy statement.

No other material transactions, financial results or leadership changes were disclosed in this filing.

Positive

• None.

Negative

• Share reserve under the equity incentive plan increased by 17.4 million shares, expanding potential dilution by approximately 4.6% if fully issued.

Insights

Corporate Governance Analyst

TL;DR: All proposals passed; governance signals remain stable, impact largely neutral for near-term valuation.

Shareholder participation above 85% demonstrates strong engagement. Director elections and Say-on-Pay received >96% support, indicating institutional satisfaction with board composition and compensation structures. PwC’s re-appointment maintains audit continuity. The 17.4 million-share increase in the equity plan equals roughly 4.6% of current shares outstanding, giving the board additional flexibility to attract talent but modestly expanding potential dilution. Overall, the actions are routine for a mid-cap life-science tools company and do not materially alter the investment thesis.

Equity Compensation Specialist

TL;DR: Larger share reserve boosts incentive capacity; dilution risk modest but manageable.

The newly approved reserve lifts the plan’s headroom by 17.4 million shares. Assuming full issuance, outstanding share count could rise by ~4.6%. While this is not excessive, investors should monitor grant pacing and burn-rate metrics in future proxy statements. High approval (91.8% of votes cast) suggests shareholders are comfortable with current equity usage levels and governance controls (e.g., vesting schedules, performance criteria). Because no immediate issuance occurs, short-term EPS impact is negligible; long-term effects depend on subsequent grant activity.

8-K Event Classification

3 items: 5.02, 5.07, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001162194false00011621942025-06-182025-06-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): June 18, 2025

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-34180 (Commission File Number)	77-0513190 (I.R.S. Employer Identification Number)
2 Tower Place, Suite 2000 South San Francisco, California 94080
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock, $0.001 par value per share		LAB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Standard BioTools Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 18, 2025. The Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated 2011 Equity Incentive Plan, as amended (the “Plan”), increasing the number of shares of common stock reserved for issuance thereunder by 17,400,000 shares.

The Plan is described in further detail in the Company’s definitive proxy statement on Schedule 14A for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2025 (the “Proxy Statement”), which description is incorporated herein by reference. The complete text of the Plan is set forth in Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On April 25, 2025 (the “Record Date”), the Company had 379,822,268 shares of common stock issued and outstanding. A total of 326,864,517 votes, or approximately 86.06% of the total voting power of the shares of the Company’s capital stock issued and outstanding and entitled to vote at the Annual Meeting were represented in person or by proxy at the Annual Meeting. The following proposals are described in detail in the Proxy Statement. The final voting results for each of the matters submitted to a stockholder vote at the Annual Meeting are set forth below:

1. Election of Class III Directors. The following nominees were elected to serve as Class III directors, to hold office until the Company’s 2028 annual meeting of stockholders or until their respective successors have been duly elected and qualified or their earlier resignation or removal:

Nominee		Votes For		Votes Withheld		Broker Non-Votes
Kathy Hibbs		235,917,851		9,416,470		81,530,196
Frank Witney, Ph.D.		240,269,516		5,064,805		81,530,196

2. Advisory Vote on Approval of Executive Compensation. The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers for the year ended December 31, 2024 was approved by the following votes:

Votes For		Votes Against		Abstentions		Broker Non-Votes
241,143,534		4,006,163		184,624		81,530,196

3. Ratification of Appointment of Independent Registered Public Accounting Firm. The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025 was approved by the following vote:

Votes For		Votes Against		Abstentions
322,915,281		3,650,720		298,516

4. Approval of the Amendment to the Amended and Restated 2011 Equity Incentive Plan, as Amended. The proposal to approve the amendment to the Plan to increase the shares of common stock reserved thereunder by 17,400,000 shares was approved by the following votes:

Votes For		Votes Against		Abstentions		Broker Non-Votes
223,394,563		19,589,973		2,349,785		81,530,196

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1+		Standard BioTools Inc. Amended and Restated 2011 Equity Incentive Plan, as Amended.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

________________________

+ Management compensation plan or arrangement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:		June 20, 2025		STANDARD BIOTOOLS INC.
				By:		/s/ Alex Kim
				Name:		Alex Kim
				Title:		Chief Financial Officer

FAQ

How many votes were represented at Standard BioTools' 2025 Annual Meeting?

326,864,517 votes, or about 86.06% of shares outstanding, were present in person or by proxy.

Did shareholders approve the 2025 Say-on-Pay proposal for LAB?

Yes. Executive compensation received 241.1 million FOR votes (97.0% support).

What change was made to Standard BioTools' 2011 Equity Incentive Plan?

The share reserve was increased by 17,400,000 shares following shareholder approval.

Who were elected as Class III directors at Standard BioTools in 2025?

Kathy Hibbs and Frank Witney, Ph.D. were elected to serve until the 2028 annual meeting.

Was PricewaterhouseCoopers LLP re-appointed as LAB's auditor?

Yes. PwC was ratified with 322.9 million FOR votes versus 3.7 million AGAINST.